Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Recombinant monoclonal antibodies (mAbs) have been driving the rapid growth of commercial biotherapeutics, and have led to the development of more complex antibody-drug conjugates (ADCs), bi-specific antibodies (BsAb), and fusion proteins. During production these molecules are susceptible to chemical modifications due to a variety of cellular processes, manufacturing conditions, and chemical degradation [[1], [2], [3], [4]].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
